Skip to main content
Have a personal or library account? Click to login
Radiotherapy in combination with vascular-targeted therapies Cover

Radiotherapy in combination with vascular-targeted therapies

Radiology and Oncology
Volume 44 (2010): Issue 2 (June 2010)
By:  and    
Open Access
|May 2010
References

References

  1. Ringborg U, Bergqvist D, Brorsson B, Cavallin-Ståhl E, Ceberg J, Einhorn N, et al. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001—summary and conclusions.2003; 42: 357-65.
    Open DOISearch in Google Scholar
  2. McGinn CJ, Shewach, DS, Lawrence TS. Radiosensitizing nucleosides.1996; 88: 1193-203.
    Open DOISearch in Google Scholar
  3. Wachsberger P, Burd R, Dicker AP. Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways.2004; 18: 1039-57.
    Open DOISearch in Google Scholar
  4. Folkman J. Tumor angiogenesis: therapeutic implications.1971; 285: 1182-6.
    Open DOISearch in Google Scholar
  5. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases.2000; 407: 249-57.
    Open DOISearch in Google Scholar
  6. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.1996; 86: 353-64.
    Open DOISearch in Google Scholar
  7. Los M, Voest EE. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer.2001; 28: 93-105.
    Open DOISearch in Google Scholar
  8. Ferrara N, Gerber HP. The role of vascular endothelial growth factor in angiogenesis.2001; 106: 148-56.
    Open DOISearch in Google Scholar
  9. Jain RK. Molecular regulation of vessel maturation.2003; 9: 685-93.
    Open DOISearch in Google Scholar
  10. Risau W. Mechanisms of angiogenesis.1997; 386: 671-4.
    Open DOISearch in Google Scholar
  11. Liu W, Ahmad SA, Reinmuth N, Shaheen RM, Jung YD, Fan F, et al. Endothelial cell survival and apoptosis in the tumor vasculature.2000; 5: 323-8.
    Open DOISearch in Google Scholar
  12. Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).2005; 9: 777-94.
    Open DOISearch in Google Scholar
  13. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen.1989; 246: 1306-9.
    Open DOISearch in Google Scholar
  14. Nicosia RF, Tchao R, Leighton J. Interactions between newly formed endothelial channels and carcinoma cells in plasma clot culture.1986; 4: 91-104.
    Open DOISearch in Google Scholar
  15. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice.2001; 61: 2207-11.
    Search in Google Scholar
  16. O'Reilly MS. Antiangiogenesis: basic principles. In: Rosenberg SA, editor.3edition. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 827-43.
    Search in Google Scholar
  17. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy.2001; 7: 987-9.
    Open DOISearch in Google Scholar
  18. Jain RK. Determinants of tumor blood flow: a review.1988; 48: 2641-58.
    Search in Google Scholar
  19. Jain RK. Transport of molecules, particles, and cells in solid tumors.1999; 1: 241-63.
    Open DOISearch in Google Scholar
  20. Wouters BG, Koritzinsky M. The tumor microenvironment and cellular hypoxia responses. In: Joiner M, van der Kogel AJ, editors.4edition. London: A Hodder Arnold Publication; 2009. p. 217-32.
    Open DOISearch in Google Scholar
  21. Carmeliet P. Angiogenesis in health and disease.2003; 9: 653-60.
    Open DOISearch in Google Scholar
  22. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.2005; 23: 1011-27.
    Open DOISearch in Google Scholar
  23. Harris AL. Hypoxia - a key regulatory factor in tumor growth.2002; 2: 38-47.
    Open DOISearch in Google Scholar
  24. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules.2004; 5: 429-41.
    Open DOISearch in Google Scholar
  25. Gu J, Yamamoto H, Ogawa M, Ngan CY, Danno K, Hemmi H, et al. Hypoxiainduced up-regulation of angiopoietin-2 in colorectal cancer.2006; 15: 779-83.
    Search in Google Scholar
  26. Kuwabara K, Ogawa S, Matsumoto M, Koga S, Clauss M, Pinsky DJ, et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells.1995; 92: 4606-10.
    Open DOISearch in Google Scholar
  27. Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pissakas G, Gatter KC, et al. Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy.2001; 21: 4301-9.
    Search in Google Scholar
  28. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.1999; 59: 3374-8.
    Search in Google Scholar
  29. Chapman JD, Dugle DL, Reuvers AP, Meeker BE, Borsa J. Studies on the radiosensitizing effect of oxygen in Chinese hamster cells.1974; 26: 383-9.
    Open DOISearch in Google Scholar
  30. Patterson DM, Rustin GJ. Vascular damaging agents.2007; 19: 443-56.
    Open DOISearch in Google Scholar
  31. Giaccia AJ. Hypoxic stress proteins: survival of the fittest.1996; 6: 46-58.
    Open DOISearch in Google Scholar
  32. Jung YD, Ahmad SA, Liu W, Reinmuth N, Parikh A, Stoeltzing O, et al. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis.2002; 12: 105-12.
    Open DOISearch in Google Scholar
  33. Siemann DW, Bibby MC, Dark GG, Dicker AP, Eskens FA, Horsman MR, et al. Differentiation and definition of vascular-targeted therapies.2005; 11: 416-20.
    Open DOISearch in Google Scholar
  34. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity.2008; 8: 579-91.
    Open DOISearch in Google Scholar
  35. Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells.2005; 24: 2647-53.
    Open DOISearch in Google Scholar
  36. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.2007; 6: 471-83.
    Open DOISearch in Google Scholar
  37. Kamensek U, Sersa G. Targeted gene therapy in radiotherapy.2008; 42: 115-35.
    Open DOISearch in Google Scholar
  38. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.2004; 350: 2335-42.
    Open DOISearch in Google Scholar
  39. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.2006; 355: 2542-50.
    Open DOISearch in Google Scholar
  40. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.2005; 23: 792-9.
    Open DOISearch in Google Scholar
  41. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomized double-blind phase III trial.2007; 370: 2103-11.
    Open DOISearch in Google Scholar
  42. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.2007; 356: 115-24.
    Open DOISearch in Google Scholar
  43. Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis.2004; 2: 36-42.
    Open DOISearch in Google Scholar
  44. Thorpe PE. Vascular targeting agents as cancer therapeutics.2004; 10: 415-27.
    Open DOISearch in Google Scholar
  45. Baguley BC. Antivascular therapy of cancer: DMXAA.2003; 4: 141-8.
    Open DOISearch in Google Scholar
  46. Tozer GM, Prise VE, Wilson J, Cemazar M, Shan S, Dewhirst MW, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.2001; 61: 6413-22.
    Search in Google Scholar
  47. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours.2008; 34: 232-40.
    Open DOISearch in Google Scholar
  48. Sersa G, Jarm T, Kotnik T, Coer A, Podkrajsek M, Sentjurc M, et al. Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma.2008, 98: 388-98.
    Open DOISearch in Google Scholar
  49. Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Kotnik V, et al. Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin.2002; 87: 1047-54.
    Open DOISearch in Google Scholar
  50. Coer A, Cemazar M, Plaza N, Sersa G. Comparison between hypoxic markers pimonidazole and glucose transporter 1 (Glut-1) in murine fibrosarcoma tumours after electrochemotherapy.2009; 43: 195-202.
    Search in Google Scholar
  51. Citrin D, Camphausen K. Advancement of antiangiogenic and vascular disrupting agents combined with radiation. In: Mehta MP, editor.New York: Springer Science; 2008. p. 150-68.
    Open DOISearch in Google Scholar
  52. Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents.1994; 57: 920-5.
    Open DOISearch in Google Scholar
  53. Teicher BA, Holden SA, Ara G, Korbut T, Menon K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma.1996; 38: 169-77.
    Open DOISearch in Google Scholar
  54. Murata R, Nishimura Y, Hiraoka M. An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma.1997; 37: 1107-13.
    Open DOISearch in Google Scholar
  55. Lund EL, Bastholm L, Kristjansen PE. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts.2000; 6: 971-8.
    Search in Google Scholar
  56. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA, et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy.1998; 394: 287-91.
    Open DOISearch in Google Scholar
  57. Hanna NN, Seetharam S, Mauceri HJ, Beckett MA, Jaskowiak NT, Salloum RM, et al. Antitumor interaction of short-course endostatin and ionizing radiation.2000; 6: 287-93.
    Search in Google Scholar
  58. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.1999; 59: 3374-8.
    Search in Google Scholar
  59. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.2000; 60: 5565-70.
    Search in Google Scholar
  60. Gupta VK, Jaskowiak NT, Beckett MA, Mauceri HJ, Grunstein J, Johnson RS, et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance.2002; 8: 47-54.
    Open DOISearch in Google Scholar
  61. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.2001; 61: 2413-9.
    Search in Google Scholar
  62. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiationinduced longterm control of human tumor xenografts.2001; 61: 39-44.
    Search in Google Scholar
  63. Fenton BM, Paoni SF, Ding I. Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors.2004; 64: 5712-9.
    Open DOISearch in Google Scholar
  64. Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, et al. Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumor growth.2001; 85: 2010-6.
    Open DOISearch in Google Scholar
  65. Williams KJ, Telfer BA, Brave S, Kendrew J, Whittaker L, Stratford IJ, et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.2004; 10: 8587-93.
    Open DOISearch in Google Scholar
  66. Brazelle WD, Shi W, Siemann DW. VEGF associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.2006; 65: 836-41.
    Open DOISearch in Google Scholar
  67. Cao C, Albert JM, Geng L, Ivy PS, Sandler A, Johnson DH, et al. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer.2006; 66: 11409-15.
    Open DOISearch in Google Scholar
  68. Williams KJ, Telfer BA, Shannon AM, Babur M, Stratford IJ, Wedge SR. Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit.2007; 6: 599-606.
    Open DOISearch in Google Scholar
  69. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E, Mendel D, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models.2003; 63: 4009-16.
    Search in Google Scholar
  70. Lu B, Geng L, Musiek A, Tan J, Cao C, Donnelly E, et al. Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium.2004; 58: 844-50.
    Open DOISearch in Google Scholar
  71. Wachberger P, Burd R, Dicke AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.2003; 9: 1957-71.
    Search in Google Scholar
  72. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.2005; 307: 58-62.
    Open DOISearch in Google Scholar
  73. Shannon, A. M., Williams, K. J. Antiangiogenics and radiotherapy.2008; 60: 1029-36.
    Open DOISearch in Google Scholar
  74. Horsman MR, Siemann DW. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.2006; 66:11520-39.
    Open DOISearch in Google Scholar
  75. Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent.2002; 54: 1491-6.
    Open DOISearch in Google Scholar
  76. Sersa G, Willingham V, Milas L. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy.1988; 42: 129-34.
    Open DOISearch in Google Scholar
  77. Nishiguchi I, Willingham V, Milas L. Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors.1990; 18: 555-8.
    Open DOISearch in Google Scholar
  78. Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia, and radiation.2001; 40: 497-503.
    Open DOISearch in Google Scholar
  79. Wilson WW, Li AE, Cowan D, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.1998; 42: 905-8.
    Open DOISearch in Google Scholar
  80. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone- 4-acetic acid.2001; 156: 503-9.
    Open DOISearch in Google Scholar
  81. Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy.1998; 42: 899-903.
    Open DOISearch in Google Scholar
  82. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumor therapy: evaluation of combretastatin A4 phosphate.1999; 19: 189-96.
    Search in Google Scholar
  83. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors.2001; 60: 155-61.
    Open DOISearch in Google Scholar
  84. Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma.2002; 41: 91-7.
    Open DOISearch in Google Scholar
  85. Ahmed B, Landuyt W, Griffioen AW, van Oosterom A, van den Bogaert W, Lambin P. In vivo antitumor effect of combretastatin A-4 phosphate added to fractionated radiation.2006; 26: 307-10.
    Search in Google Scholar
  86. Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response.2003; 57: 1047-55.
    Open DOISearch in Google Scholar
  87. Raben D, Bianco C, Damiano V, Bianco R, Melisi D, Mignogna C, et al. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human nonsmall cell lung cancer xenograft model.2004; 3: 977-83.
    Open DOISearch in Google Scholar
  88. Wachsberger PR, Burd R, Marero N, Daskalakis C, Ryan A, McCue P, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma.2005; 11: 835-42.
    Open DOISearch in Google Scholar
  89. Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors.2005; 62: 846-53.
    Open DOISearch in Google Scholar
  90. Shi W, Siemann DW. Preclinical studies of the novel vascular disrupting agent MN-029.2005; 25: 3899-904.
    Search in Google Scholar
  91. Siemann DW, Horsman MR. Targeting the tumor vasculature: a strategy to improve radiation therapy.2004; 4: 321-7.
    Open DOISearch in Google Scholar
  92. Sersa G, Kranjc S, Cemazar M. Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors.2000; 46: 1037-41.
    Open DOISearch in Google Scholar
  93. Kranjc S, Cemazar M, Grosel A, Scancar J, Sersa G. Electroporation of LPB sarcoma cells in vitro and tumors in vivo increases radiosensitizing effect of cisplatin.2003; 23: 275-82.
    Search in Google Scholar
  94. Kranjc S, Grosel A, Cemazar M, Sentjurc M, Sersa G. Improvement of combined modality therapy with bleomycin and radiation using electroporation of LPB sarcoma cells and tumors in mice.2005; 5: 115.
    Open DOISearch in Google Scholar
  95. Kranjc S, Tevz G, Kamensek U, Vidic S, Cemazar M, Sersa G. Radiosensitizing effect of electrochemotherapy in a fractionated radiation regime in radiosensitive murine sarcoma and radioresistant adenocarcinoma tumor model.2009; 172: 677-85.
    Open DOISearch in Google Scholar
  96. Sersa G, Cemazar M, Rudolf Z, Fras AP. Adenocarcinoma skin metastases treated by electrochemotherapy with cisplatin combined with radiation.1999; 33: 291-6.
    Search in Google Scholar
  97. Tamaskar I, Pili R. Update on novel agents in renal cell carcinoma.2009; 9: 1817-27.
    Open DOISearch in Google Scholar
  98. Zhu AX, Duda DG, Sahani DV, Jain RK. Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.2009; 15: 263-8.
    Open DOISearch in Google Scholar
  99. Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma.2009; 43: 1-8.
    Open DOISearch in Google Scholar
  100. Pallis AG, Serfass L, Dziadziusko R, van Meerbeeck JP, Fennell D, Lacombe D, et al. Targeted therapies in the treatment of advanced/metastatic NSCLC.2009; 45: 2473-87.
    Open DOISearch in Google Scholar
  101. Yang SX. Bevacizumab and breast cancer: current therapeutic progress and future perspectives.2009; 9: 1715-25.
    Open DOISearch in Google Scholar
  102. Seiwert TY, Haraf DJ, Cohen EE, Stenson K, Witt ME, Dekker A, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.2008; 26: 1732-41.
    Open DOISearch in Google Scholar
  103. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.2008; 71: 1372-80.
    Open DOISearch in Google Scholar
  104. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.2009; 27: 3020-6.
    Open DOISearch in Google Scholar
  105. Koukourakis MI, Giatromanolaki A, Sheldon H, Buffa FM, Kouklakis G, Ragoussis I, et al. Tumor and Angiogenesis Research Group. Phase I/II trial of bevacizumab and radiotherapy for locally advanced inoperable colorectal cancer: vasculature-independent radiosensitizing effect of bevacizumab.2009; 15: 7069-76.
    Open DOISearch in Google Scholar
  106. Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, et al. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.2009; 27: 4096-102.
    Open DOISearch in Google Scholar
  107. Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.2010; 28: 43-8.
    Open DOISearch in Google Scholar
  108. Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response.2009; 115: 3571-80.
    Open DOISearch in Google Scholar
  109. Ng QS, Goh V, Carnell D, Meer K, Padhani AR, Saunders MI, et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.2007; 67: 1375-80.
    Open DOISearch in Google Scholar
  110. Gridelli C, Rossi A, Maione P, Rossi E, Castaldo V, Sacco PC, et al. Vascular disrupting agents: a novel mechanism of action in the battle against nonsmall cell lung cancer.2009; 14: 612-20.
    Open DOISearch in Google Scholar
  111. Heath VL, Bicknell R. Anticancer strategies involving the vasculature.2009; 6: 395-404.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10019-010-0025-9 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 67 - 78
Published on: May 24, 2010
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
antiangiogenic agents,
vascular-disrupting agents,
radiotherapy
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2010 Eva Ciric, Gregor Sersa, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons License.

Volume 44 (2010): Issue 2 (June 2010)
Next article